Search Results for: car t

SCCR33 – Statement by the Latin American and Caribbean Group (GRULAC) – Limitations on liability for libraries and archives

Posted on by Thiru

On Thursday afternoon, 17 November 2016, WIPO’s Standing Committee on Copyright and Related Rights (SCCR) addressed the topic of limitations on liability for libraries and archives. Chile, on behalf of the Latin Americas and Caribbean Group (GRULAC) provided a poignant example of how limitations on liability for libraries and archives enabled the provision of an accurate account and attribution of the role played by the Brazilian diplomat, Bertha Lutz, and other Latin American delegates in ensuring gender equity in the UN Charter of 1945.

Continue Reading →

Harvoni & Sovaldi, Xtandi in Top 20 Costliest Medicare Drugs

Posted on by Zack Struver

The Associated Press recently released a chart from the Centers for Medicare and Medicaid Services’ Office of the Actuary that outlines spending for the top 20 costliest drugs to Medicare in 2015 after reaching Medicare’s catastrophic spending threshold: http://www.nytimes.com/aponline/2016/07/25/us/ap-us-medicare-pricey-drugs-glance.html.

UPDATE: The AP also released another story, on July 24, 2016, outlining the overall program costs of catastrophic spending and explaining various spending increases: http://www.nytimes.com/aponline/2016/07/24/us/politics/ap-us-medicare-pricey-drugs.html.

top-20-medicare-drugs-2015.png
Continue Reading →

Uncategorized

NIH to taxpayers — we don’t care about high prices in US for Xtandi

Posted on by KEI Staff

National Institutes of Health Declines to Exercise Authority to Lower Xtandi Price
The National Institutes of Health will not use its rights under the Bayh-Dole Act to end the monopoly on the expensive prostate cancer drug Xtandi and allow low-priced generic versions to compete on the market.
Continue Reading →

Biolyse Pharma offers to supply enzalutamide (Xtandi) for $3 per pill to Medicare and developing countries

Posted on by Zack Struver

On April 22, 2016, the President of Biolyse Pharma — a Canadian pharmaceutical company that specializes in the manufacture of oncology drugs — offered to supply the prostate cancer drug enzalutamide (Xtandi) to the Centers for Medicare & Medicaid Services (CMS) for $3 per pill ($12 per day; $4,383 per year). The Biolyse price for enzalutamide is 4-percent of the 2014 Medicare price, $69.41 ($277.64 per day; $101,408.01 per year), and lower than any other price in the world.

Continue Reading →

WIPO General Assembly 2015: Opening statement of Brazil on behalf of the Group of Latin and the Caribbean Group (GRULAC)

Posted on by Thiru

On Monday, 5 October 2015, Brazil delivered the following opening statement on behalf of the Group of Latin and the Caribbean Group (GRULAC) at the World Intellectual Property Organization’s (WIPO) General Assembly.

Statement Delivered by the Delegation of Brazil on behalf of GRULAC

“Mr President,

1. I have the honor to deliver this statement on behalf of the Latin American and the Caribbean Group (GRULAC).

Continue Reading →

Uncategorized

6 Members of Congress Write to President Obama on TPP and Access to Health Care, Criticize Closed Door Negotiations

Posted on by Krista Cox

On 9 December 2013, six members of Congress sent a letter to President Obama citing concerns in the TPP regarding access to health care and affordable medicines. The six members include Representatives Jan Schakowsky (D-IL), Michael Michaud (D-ME), Rosa DeLauro (D-CT), George Miller (D-CA), Barbara Lee (D-CA) and Peter Welch (D-MA). The letter primarily addresses efforts by USTR that result in greater monopoly power and delay entry of generic medicines, and how such efforts will affect state and federal budgets. Continue Reading →

Uncategorized